Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Martine Piccart-Gebhart, Eileen Holmes, José Baselga, Evandro de Azambuja, Amylou C. Dueck, Giuseppe Viale, Jo Anne Zujewski, Aron Goldhirsch, Alison Armour, Kathleen I. Pritchard, Ann E. McCullough, Stella Dolci, Eleanor McFadden, Andrew P. Holmes, Liu Tonghua, Holger Eidtmann, Phuong Dinh, Serena Di Cosimo, Nadia Harbeck, Sergei Tjulandin, Young-Hyuck Im, Chiun-Sheng Huang, Véronique Diéras, David W. Hillman, Antonio C. Wolff, Christian Jackisch, Istvan Lang, Michael Untch, Ian Smith, Frances Boyle, Binghe Xu, Henry Gomez, Thomas Suter, Richard D. Gelber, Edith A. Perez

Open source

DOI: 10.1200/jco.2015.62.1797
Published: 2016-04-01
Container: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco.2015.62.1797,
  title = {Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial},
  author = {Martine Piccart-Gebhart and Eileen Holmes and José Baselga and Evandro de Azambuja and Amylou C. Dueck and Giuseppe Viale and Jo Anne Zujewski and Aron Goldhirsch and Alison Armour and Kathleen I. Pritchard and Ann E. McCullough and Stella Dolci and Eleanor McFadden and Andrew P. Holmes and Liu Tonghua and Holger Eidtmann and Phuong Dinh and Serena Di Cosimo and Nadia Harbeck and Sergei Tjulandin and Young-Hyuck Im and Chiun-Sheng Huang and Véronique Diéras and David W. Hillman and Antonio C. Wolff and Christian Jackisch and Istvan Lang and Michael Untch and Ian Smith and Frances Boyle and Binghe Xu and Henry Gomez and Thomas Suter and Richard D. Gelber and Edith A. Perez},
  year = {2016},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco.2015.62.1797},
  url = {https://doi.org/10.1200/jco.2015.62.1797}
}

RIS

TY  - JOUR
TI  - Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
AU  - Martine Piccart-Gebhart
AU  - Eileen Holmes
AU  - José Baselga
AU  - Evandro de Azambuja
AU  - Amylou C. Dueck
AU  - Giuseppe Viale
AU  - Jo Anne Zujewski
AU  - Aron Goldhirsch
AU  - Alison Armour
AU  - Kathleen I. Pritchard
AU  - Ann E. McCullough
AU  - Stella Dolci
AU  - Eleanor McFadden
AU  - Andrew P. Holmes
AU  - Liu Tonghua
AU  - Holger Eidtmann
AU  - Phuong Dinh
AU  - Serena Di Cosimo
AU  - Nadia Harbeck
AU  - Sergei Tjulandin
AU  - Young-Hyuck Im
AU  - Chiun-Sheng Huang
AU  - Véronique Diéras
AU  - David W. Hillman
AU  - Antonio C. Wolff
AU  - Christian Jackisch
AU  - Istvan Lang
AU  - Michael Untch
AU  - Ian Smith
AU  - Frances Boyle
AU  - Binghe Xu
AU  - Henry Gomez
AU  - Thomas Suter
AU  - Richard D. Gelber
AU  - Edith A. Perez
PY  - 2016
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco.2015.62.1797
UR  - https://doi.org/10.1200/jco.2015.62.1797
ER  -

APA

Piccart-Gebhart, M., Holmes, E., Baselga, J., Azambuja, E. D., Dueck, A. C., Viale, G., Zujewski, J. A., Goldhirsch, A., Armour, A., Pritchard, K. I., McCullough, A. E., Dolci, S., McFadden, E., Holmes, A. P., Tonghua, L., Eidtmann, H., Dinh, P., Cosimo, S. D., Harbeck, N., Tjulandin, S., Im, Y., Huang, C., Diéras, V., Hillman, D. W., Wolff, A. C., Jackisch, C., Lang, I., Untch, M., Smith, I., Boyle, F., Xu, B., Gomez, H., Suter, T., Gelber, R. D., & Perez, E. A. (2016). Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.62.1797

Source records

crossref · retrieved 2026-09-26T09:37:27.674Z